Millendo Therapeutics – Consensus Indicates Potential 77.8% Upside

Broker Ratings

Millendo Therapeutics found using ticker (MLND) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 5 and 2 with the average target price sitting at 4. Now with the previous closing price of 2.25 this now indicates there is a potential upside of 77.8%. The 50 day moving average now sits at 1.79 and the 200 day MA is 1.79. The company has a market capitalisation of $43m. Find out more information at: http://www.millendo.com

Millendo Therapeutics, a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp

AIM All Share Index